SM
ABUS icon

Sabby Management’s Arbutus Biopharma ABUS Stock Holding History

Sabby Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-248,600
Closed -$895K – 166
2017
Q2 		$895K Sell
248,600
-399,600
-62% -$1.37M 0.06% 109
2017
Q1 		$2.11M Sell
648,200
-144,417
-18% -$401K 0.11% 87
2016
Q4 		$1.94M Sell
792,617
-85,914
-10% -$250K 0.11% 104
2016
Q3 		$3.02M Sell
878,531
-297,500
-25% -$1.16M 0.11% 100
2016
Q2 		$4.09M Sell
1,176,031
-21,307
-2% -$90.2K 0.21% 65
2016
Q1 		$4.95M Buy
1,197,338
+197,338
+20% +$705K 0.25% 42
2015
Q4 		$4.45M Buy
1,000,000
+274,993
+38% +$1.51M 0.24% 68
2015
Q3 		$4.42M Buy
725,007
+419,656
+137% +$3.72M 0.18% 93
2015
Q2 		$3.62M Buy
305,351
+134,530
+79% +$2.05M 0.13% 116
2015
Q1 		$2.98M Buy
+170,821
New +$3.5M 0.12% 112
2014
Q1 		– Sell
-519,200
Closed -$9.33M – 233
2013
Q4 		$4.14M Buy
+519,200
New +$4.32M 0.26% 56

Other funds holding ABUS

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sabby Management's ABUS Position: Q3 2017 in Review

Sabby Management sold out of Arbutus Biopharma (ABUS) in Q3 2017, closing a stake of 248,600 shares — an estimated $895K sold.

Sabby Management first reported a position in ABUS in Q4 2013 and held it in 11 quarters. The position peaked at $4.95M in Q1 2016. 53 funds tracked by Wall St. Rank hold ABUS as of Q3 2017.

  • Sabby Management reported no remaining Arbutus Biopharma position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 248,600 Arbutus Biopharma shares in Q3 2017, an estimated $895K.
  • Sabby Management first reported a position in Arbutus Biopharma in Q4 2013 and held it in 11 quarters.
  • Sabby Management's Arbutus Biopharma position peaked at $4.95M in Q1 2016.
  • 53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.